MedTrace Logo

Impact of Genetics on Metformin Pharmacokinetics

NCT00187798 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-09-25

No results posted yet for this study

Summary

Specific Aims: To compare metformin pharmacokinetics in monozygotic and dizygotic twin pairs. Comparing renal clearance of metformin in monozygotic and dizygotic twins will allow us to better understand the influence of heredity on variation in renal elimination. Furthermore, genotyping renal transporter genes in monozygotic and dizygotic twin pairs with significant differences in renal clearance of metformin may give us insight into the genes responsible for this variability.

Conditions

  • Other Conditions That May Be A Focus of Clinical Attention

Interventions

DRUG

Metformin HCl

Subjects will be given a single oral dose in tablet form containing 850 mg of metformin

Sponsors & Collaborators

Principal Investigators

  • Kathleen Giacomini, PhD · University of California San Francsico

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-08-31
Primary Completion
2007-07-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00187798 on ClinicalTrials.gov